Is flecainide dangerous in long QT-3 patients?

Pacing Clin Electrophysiol. 2009 Jan;32(1):143-5. doi: 10.1111/j.1540-8159.2009.02190.x.

Abstract

Mutations of the cardiac sodium channel gene, SCN5A, are present in both long-QT and Brugada syndromes. Flecainide is used as a provocative test to unmask the electrocardiogram (ECG) phenotype of the Brugada syndrome, as well as long-term treatment for long QT-3 syndrome, since it shortens the QT interval. We report a case where oral flecainide induced syncope with a Brugada ECG pattern in a patient with known long QT-3 syndrome.

Publication types

  • Case Reports

MeSH terms

  • Anti-Arrhythmia Agents / adverse effects
  • Brugada Syndrome / complications
  • Brugada Syndrome / diagnosis*
  • Electrocardiography / drug effects*
  • Female
  • Flecainide / adverse effects*
  • Humans
  • Long QT Syndrome / complications
  • Long QT Syndrome / diagnosis*
  • Syncope / chemically induced*
  • Syncope / diagnosis*
  • Young Adult

Substances

  • Anti-Arrhythmia Agents
  • Flecainide